<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04515472</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20190415H</org_study_id>
    <nct_id>NCT04515472</nct_id>
  </id_info>
  <brief_title>Effect of Gender Affirming Hormone Therapy on Glucose Metabolism</brief_title>
  <official_title>Effect of Gender Affirming Hormone Therapy on Glucose Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation for advancing Veterans Health Research (FAVHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will test:&#xD;
&#xD;
        1. whether estrogen treatment in transwomen is associated with improved insulin sensitivity&#xD;
           and beta cell function&#xD;
&#xD;
        2. whether testosterone treatment in transmen is associated with worsening insulin&#xD;
           sensitivity and beta cell function&#xD;
&#xD;
        3. whether estrogen therapy leads to enhanced immune response in older transwormen&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will participate in a 2-hour oral glucose tolerance test (OGTT) and DXA scan for&#xD;
      estimation of lean body mass. Only the transgender subjects will have a repeat OGTT two weeks&#xD;
      after discontinuation of Gender Affirming Hormone Therapy (GAHT).&#xD;
&#xD;
      Beta cell function will be correlated with the Estrogen/Testosterone ratio to evaluate the&#xD;
      relationship between sex hormones and beta cell function. Plasma Glucagon-like peptide 1&#xD;
      (GLP-1) response during the OGTT will be measured to evaluate if estrogen treatment modulates&#xD;
      insulin secretion by increasing GLP-1 secretion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>MTF and FTM non-diabetic transsexuals will be compared to healthy female and male subjects respectively.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of Chronic estrogen therapy on insulin secretion</measure>
    <time_frame>Baseline to 180 minutes</time_frame>
    <description>Change in GLP-1 in response to glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of Chronic estrogen therapy on insulin sensitivity</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in beta cell function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of Chronic testosterone therapy on insulin secretion</measure>
    <time_frame>Baseline to 180 minutes</time_frame>
    <description>Change in GLP-1 in response to glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of Chronic testosterone therapy on insulin sensitivity</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in beta cell function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response change</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Withhold GAHT for 2 weeks after Botnia Clamp</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Transgender Persons</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteer Male</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy male currently on no testosterone treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteer Female</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy female currently on no estrogen treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTF group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MTF transgender currently on estrogen treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FTM group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FTM transgender group currently on testosterone treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botnia Clamp</intervention_name>
    <description>This clamp technique is designed to obtain independent measures of insulin secretion and insulin sensitivity during the same test. In brief, 0.3g/kg body wt of a 20% glucose solution is given at time 0. Blood samples for the measurement of plasma glucose and serum insulin are obtained at -10, 0, 2, 4, 6, 8, 10, 20, 30, 40, 50, 60, 120, and 180 min.</description>
    <arm_group_label>FTM group</arm_group_label>
    <arm_group_label>Healthy Volunteer Female</arm_group_label>
    <arm_group_label>Healthy Volunteer Male</arm_group_label>
    <arm_group_label>MTF group</arm_group_label>
    <other_name>Glucose solution and insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Withdrawal of Gender Affirming Hormone Therapy (GAHT)</intervention_name>
    <description>GAHT, either estrogen or testosterone therapy will be withdrawn after the Botnia Clamp.</description>
    <arm_group_label>FTM group</arm_group_label>
    <arm_group_label>MTF group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers: healthy male or female&#xD;
&#xD;
          -  MTF transgender&#xD;
&#xD;
          -  FTM transgender&#xD;
&#xD;
          -  Non-diabetic (A1c&lt;6.5%), fasting glucose &lt;126mg/dl and OGTT after 2 hr &lt;200mg/dl)&#xD;
&#xD;
          -  Stable hormone treatment (estrogen or testosterone) for at least 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of or newly diagnosed diabetes mellitus&#xD;
&#xD;
          -  For healthy volunteers, not current treatment with estrogen or testosterone&#xD;
&#xD;
          -  For FTM transgender, no recent cardiovascular event: acute coronary syndrome (ACS),&#xD;
             stroke (CVA)&#xD;
&#xD;
          -  For MTF and FTM transgender, less than 6 months of stable hormone treatment&#xD;
&#xD;
          -  Anemia with hemoglobin (Hb) &lt;11.0 hematocrit (Hto) &lt; 34 and Glomerular Filtration rate&#xD;
             (GFR) &lt;30&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Devjit Tripathy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Devjit Tripathy, MD</last_name>
    <phone>210-617-5300</phone>
    <phone_ext>17822</phone_ext>
    <email>tripathy@uthscsa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emina Case</last_name>
    <phone>210-617-5300</phone>
    <phone_ext>17822</phone_ext>
    <email>morinae@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bartter Clinical Research Unit, Audie L. Murphy VA Hospital, sTXVHCS</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Devjit Tripathy, MD</last_name>
      <phone>210-617-5300</phone>
      <phone_ext>17822</phone_ext>
      <email>tripathy@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emina Case</last_name>
      <phone>210-617-5300</phone>
      <phone_ext>17822</phone_ext>
      <email>morinae@uthscsa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Devjit Tripathy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

